Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder July 24, 2023July 24, 2023 Montana Bioscience Enterprises in the News 0 Comments by Suzanne Lagoni Social Anxiety Disorder Affects 15 Million U.S. Adults and is More Common Among Women than Men Facebook Twitter Pinterest Previous Post Next Post